MIPS-21335

• Description:

  MIPS-21335 is a PI3KC2α inhibitor with an IC50 of 7 nM. MIPS-21335 also inhibits PI3KC2β, p110α, p110β and p110δ, with IC50 values of 43, 140, 386 and 742 nM, respectively. MIPS-21335 has antithrombotic effect. MIPS-21335 can be used for the researches of cardiovascular disease and metabolic disease, such as thrombosis and hyperlipidemia[1][2].

• UNSPSC:

  12352005

• Target:

  PI3K

• Type:

  Reference compound

• Related Pathways:

  PI3K/Akt/mTOR

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Metabolic Disease; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/mips-21335.html

• Purity:

  99.61

• Solubility:

  DMSO : 25 mg/mL (ultrasonic)

• Smiles:

  COC1=C2N=C(N3CCN=C3C2=CC=C1OCC4=CC([N+]([O-])=O)=CC=C4)NC(C5=CN=C(C=C5)N)=O

• Molecular Formula:

  C24H21N7O5

• Molecular Weight:

  487.47

• References & Citations:

  [1]Selvadurai MV, et al. Disrupting the platelet internal membrane via PI3KC2α inhibition impairs thrombosis independently of canonical platelet activation. Sci Transl Med. 2020 Jul 22;12 (553) :eaar8430.|[2]Setiabakti NM, et al. PI3KC2α inhibition is antithrombotic in blood from hypercholesterolemic mice. J Thromb Haemost. 2024 Jan;22 (1) :249-254.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  PI3KC2α; PI3KC2β

• CAS Number:

  [2569296-51-9]